Sun Pharma, Dr Reddy's, Cipla and Lupin are shifting R&D toward complex injectables and biosimilars as US generics pricing erodes. Sun's specialty business already crossed $1.4B. Lupin targets its first US biosimilar launch in FY27.
COOPER COMPANIES, INC. currently carries an Alpha Score of n/a, giving AlphaScala's model a neutral read on the setup.
Indian drugmakers are done fighting for scraps in US generics. The new playbook runs through complex injectables, respiratory therapies, and biosimilars – products with better pricing power and longer revenue tails.
Sun Pharma's specialty medicines business crossed $1.4 billion in FY26, now over 22% of consolidated sales. The company's Global Innovative Medicines unit is pulling growth in emerging markets, with Ilumya selling in Romania, Brazil, and China through a partner. "Innovative medicines has been an important new driver for growth in EMs for the year," COO Aalok Shanghvi said on the Q4 call.
Dr Reddy's posted its highest-ever annual revenue in FY26, CFO M V Narasimham said, despite "product-specific headwinds and certain one-time impacts." The company is leaning into differentiated products and biosimilars to sustain that run.
Cipla's Africa business is leading its geographic push. Emerging markets and Europe now form a $400 million-plus unit. MD Achin Gupta called biosimilars "a very large and underpenetrated opportunity." The company is also leaning on respiratory therapies and branded prescriptions.
Lupin's complex-product pipeline has 60-plus injectable and respiratory products in development. The company plans its first US biosimilar launch in FY27. Brazil is a standout growth market. "Our strategy of focusing on complex products has paid handsome dividends," said executive director Ramesh Swaminathan, pointing to launches like Risperdal Consta and Liraglutide.
The common thread: US generics pricing is structurally broken. Intense competition and regulatory friction have squeezed margins for years. Companies are shifting R&D dollars toward specialty therapies and branded portfolios that offer stronger margins and longer visibility. The shift is visible in management commentary across all four firms.
For investors, the question is which pipeline converts fastest. Sun Pharma's specialty revenue is already material. Lupin and Cipla are earlier in the transition. Dr Reddy's is somewhere in between. The margin trajectory for each will depend on how quickly complex products replace lost generic revenue.
The next catalyst is the US biosimilar pipeline. Lupin's FY27 target is the first concrete date on the board. If approvals come through on schedule, the specialty thesis gets a real test.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.